These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6503474)

  • 1. Sorbent therapy of the porphyrias. III. Comparative efficacy of experimental plasma perfusion with several commercial hemoperfusion cartridges.
    Tishler PV; Winston SH
    Methods Find Exp Clin Pharmacol; 1984 Jul; 6(7):389-93. PubMed ID: 6503474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorbent therapy of the porphyrias. II. Experimental plasma or hemoperfusion with a commercial charcoal cartridge.
    Tishler PV; Gordon BJ
    Methods Find Exp Clin Pharmacol; 1983; 5(3):185-91. PubMed ID: 6888085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorbent therapy of the porphyrias. V. Adsorption of the porphyrin precursors delta-aminolevulinic acid and porphobilinogen by sorbents in vitro.
    Winston SH; Tishler PV
    Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):233-7. PubMed ID: 3724299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nephrologists and porphyrias].
    Canavese C; Gabrielli D; Guida C; Cappellini MD
    G Ital Nefrol; 2002; 19(4):393-412. PubMed ID: 12369042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
    Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and simultaneous quantitation of 5-aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography-atmospheric pressure chemical ionization/tandem mass spectrometry.
    Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK
    Biomed Chromatogr; 2013 Feb; 27(2):267-72. PubMed ID: 23180457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charcoal haemoperfusion and haemodialysis in acute intermittent porphyria.
    Laiwah AC; Junor B; MacPhee GJ; Thompson GG; McColl KE
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1746-7. PubMed ID: 6416574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorbent therapy of the porphyrias. IV. Adsorption of porphyrins by sorbents in vitro.
    Tishler PV; Winston SH
    Methods Find Exp Clin Pharmacol; 1985 Sep; 7(9):485-91. PubMed ID: 4079600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute intermittent porphyria in childhood: a population-based study.
    Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
    Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms.
    Mustajoki P; Timonen K; Gorchein A; Seppäläinen AM; Matikainen E; Tenhunen R
    Eur J Clin Invest; 1992 Jun; 22(6):407-11. PubMed ID: 1633836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophyrin precursors in blood, urine and cerebrospinal fluid in acute porphyria.
    Percy VA; Shanley BC
    S Afr Med J; 1977 Jul; 52(6):219-22. PubMed ID: 897913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of clonidine in a primed rat model of acute hepatic porphyria.
    Goerz G; Bolsen K; Böhrer H; Fritsch C; Kalka K; Rominger KL
    Arzneimittelforschung; 1997 Jun; 47(6):731-3. PubMed ID: 9239451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes.
    Sardh E; Andersson DE; Henrichson A; Harper P
    Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):66-71. PubMed ID: 19268004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coated carbon hemoperfusion provides limited clearance of protein-bound solutes.
    Dinh DC; Recht NS; Hostetter TH; Meyer TW
    Artif Organs; 2008 Sep; 32(9):717-24. PubMed ID: 18684207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies of hemoperfusion devices. I. In vitro clearance characteristics.
    Cooney DO; Infantolino W; Kane R
    Biomater Med Devices Artif Organs; 1978; 6(3):199-213. PubMed ID: 728514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
    Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
    Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removal of alpha-amanitin from blood by hemoperfusion over uncoated charcoal. Experimental results.
    Masini E; Blandina P; Mannaioni PF
    Contrib Nephrol; 1982; 29():76-81. PubMed ID: 7075219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. delta-Aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects.
    Gorchein A; Webber R
    Clin Sci (Lond); 1987 Jan; 72(1):103-12. PubMed ID: 3802715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.